Market Overview

Analysis: A CVS-Aetna Merger Would Be Revolutionary

Analysis: A CVS-Aetna Merger Would Be Revolutionary
Related CVS
Raymond James: CVS A Strong Buy Despite Pricing Headwinds
Molina Wins New Bulls On Cost Saving, Margin Opportunities
Goldman bullish on Insmed in premarket analyst action (Seeking Alpha)
Related AET
Analysts Love CVS Health Shares Following Aetna Deal
9 Policy Catalysts For Health Care Investors To Watch Before Year's End
M&A Updates: CVC Capital Is Interested In French Insurer April SA (Seeking Alpha)

Health care investors were blindsided on Thursday afternoon when Dow Jones reported that CVS Health Corp (NYSE: CVS) is exploring a $66 billion bid for Aetna Inc (NYSE: AET). As expected, Wall Street analysts have a lot to say about the potential deal.

In a new note on Friday, Citigroup analyst Alvin Concepcion said a marriage between CVS and Aetna makes sense in principle as the health care industry prepares for a major new competitor in, Inc. (NASDAQ: AMZN).

“In sum, we see this potential deal as both evolutionary and revolutionary given the dynamic healthcare environment and push toward consumerism coupled with a challenged retail backdrop and the need to combat a looming AMZN threat,” Concepcion said.

A $66 billion deal would be a tough pill for the $73 billion CVS to swallow.

At roughly $200 per share, Concepcion says the price for the potential deal is reasonable. That price represents 12.4x Aetna’a trailing 12-month EBITDA, which is within the range of the valuations of previous CVS acquisitions Caremark (11.8x) and Omnicare (22.0x).

However, Concepcion said CVS has a lot to gain from the potentially difficult deal. He estimates that the buyout could contribute an additional $0.24 in EPS for CVS within a year of completion. In addition, the two companies could leverage the power of their combined data to gain additional insights about customers.

Customers themselves could also be winners from the merger, benefitting from potentially lower pharmacy prices.

Citi has a Neutral rating and $87 price target for CVS stock.

Editor's note: On Dec. 1, Dow Jones reported CVS will acquire Aetna for $145 per share in cash, plus $62 in CVS stock.

Related Link: Walgreens: A Weak Stock Is A Weak Stock

Image Credit: By Ildar Sagdejev (Specious) - Own work, GFDL, via Wikimedia Commons

Latest Ratings for CVS

Jan 2019UBSInitiates Coverage OnBuy
Dec 2018BarclaysInitiates Coverage OnOverweight
Nov 2018Goldman SachsReinstatesNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Price Target Reiteration M&A Analyst Ratings General Best of Benzinga


Related Articles (AMZN + AET)

View Comments and Join the Discussion!

Latest Ratings

EMNMorgan StanleyUpgrades90.0
DERMRaymond JamesUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

A Word In Defense Of Western Digital

Mid-Morning Market Update: Markets Mostly Higher; Amazon Beats Q3 Views